A Cost‐Effectiveness Analysis of FreeStyle Libre Real‐Time Continuous Glucose Monitoring System Compared With Self‐Monitoring of Blood Glucose in Adults With Type 2 Diabetes on Basal Insulin Plus SGLT2 Inhibitor and/or GLP ‐1 Agonists in the United K

ABSTRACT Aims We previously showed that FreeStyle Libre (FSL) real‐time continuous glucose monitoring system (rtCGM) reduces glycated haemoglobin (HbA1c) at 16 and 32 weeks compared with capillary self‐monitoring of blood glucose (SMBG) in adults with Type 2 diabetes and above target glucose levels, managed with basal insulin and SGLT‐2 inhibitor and/or GLP‐1 agonist therapy. We assess the cost‐effectiveness of rtCGM compared with SMBG. Materials and Methods Participant‐level baseline and follow‐up health status (Euroqol‐5‐dimensions‐5‐levels) and within‐trial healthcare resource‐use data were collected. We estimated quality‐adjusted life‐years (QALYs) and participant‐level costs at 16 and 32 weeks. Long‐term cost‐effectiveness from the United Kingdom National Health Service perspective was evaluated using the IQVIA CORE Diabetes Model with a 3.5% discount rate. Sensitivity analyses assessed structural and parameter uncertainty. Results Within‐trial analyses found no significant difference at 32 weeks between rtCGM and SMBG in QALYs or healthcare costs. At 32 weeks, adjusted incremental QALYs were −0.015 (95% CI: −0.031 to 0.003) and incremental costs were £254 (95% CI: −£587 to £1070). The lifetime projected incremental QALYs were 0.730 (95% CI: 0.688–0.773) and incremental costs were £4341 (95% CI: 3558–5125), generating an incremental cost‐effectiveness ratio (ICER) of £5943 per QALY. At least 4 years of maintained glycaemic benefits are required for rtCGM to be cost‐effective. Sensitivity analyses were robust to the base‐case results. Conclusions Benefits of FSL rtCGM in lowering HbA1c in people with Type 2 diabetes on basal insulin plus SGLT‐2 inhibitor and/or GLP‐1 agonist therapy is likely to justify costs through improved health outcomes and reduced long‐term costs of diabetes‐related complications.

Authors

Institutions

Publication Details

Journal
Diabetes Obesity and Metabolism
Published
2026-11-15
DOI
https://doi.org/10.1111/dom.71476
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Cost‐Effectiveness Analysis of FreeStyle Libre Real‐Time Continuous Glucose Monitoring System Compared With Self‐Monitoring of Blood Glucose in Adults With Type 2 Diabetes on Basal Insulin Plus SGLT2 Inhibitor and/or GLP ‐1 Agonists in the United K

Emma G. Wilmot, Gerry A. Rayman, Rachel Ann Elliott, Men Thi Hoang et al.
Diabetes Obesity and Metabolism
Diabetes Management and Research
article

A Cost‐Effectiveness Analysis of FreeStyle Libre Real‐Time Continuous Glucose Monitoring System Compared With Self‐Monitoring of Blood Glucose in Adults With Type 2 Diabetes on Basal Insulin Plus SGLT2 Inhibitor and/or GLP ‐1 Agonists in the United K

Emma G. Wilmot, Gerry A. Rayman, Rachel Ann Elliott, Men Thi Hoang, Mark L. Evans, Ahmed Iqbal, Thozhukat Sathyapalan, Luke Paterson, Sankalpa Neupane, PATRICK J. MOORE, Lalantha Leelarathna, Ramzi Ajjan, Sneha T. Amritlal, Pratik Choudhary, Jonathan Z M Lim, the FreeDM2 Study Group
article en

Abstract

ABSTRACT Aims We previously showed that FreeStyle Libre (FSL) real‐time continuous glucose monitoring system (rtCGM) reduces glycated haemoglobin (HbA1c) at 16 and 32 weeks compared with capillary self‐monitoring of blood glucose (SMBG) in adults with Type 2 diabetes and above target glucose levels, managed with basal insulin and SGLT‐2 inhibitor and/or GLP‐1 agonist therapy. We assess the cost‐effectiveness of rtCGM compared with SMBG. Materials and Methods Participant‐level baseline and follow‐up health status (Euroqol‐5‐dimensions‐5‐levels) and within‐trial healthcare resource‐use data were collected. We estimated quality‐adjusted life‐years (QALYs) and participant‐level costs at 16 and 32 weeks. Long‐term cost‐effectiveness from the United Kingdom National Health Service perspective was evaluated using the IQVIA CORE Diabetes Model with a 3.5% discount rate. Sensitivity analyses assessed structural and parameter uncertainty. Results Within‐trial analyses found no significant difference at 32 weeks between rtCGM and SMBG in QALYs or healthcare costs. At 32 weeks, adjusted incremental QALYs were −0.015 (95% CI: −0.031 to 0.003) and incremental costs were £254 (95% CI: −£587 to £1070). The lifetime projected incremental QALYs were 0.730 (95% CI: 0.688–0.773) and incremental costs were £4341 (95% CI: 3558–5125), generating an incremental cost‐effectiveness ratio (ICER) of £5943 per QALY. At least 4 years of maintained glycaemic benefits are required for rtCGM to be cost‐effective. Sensitivity analyses were robust to the base‐case results. Conclusions Benefits of FSL rtCGM in lowering HbA1c in people with Type 2 diabetes on basal insulin plus SGLT‐2 inhibitor and/or GLP‐1 agonist therapy is likely to justify costs through improved health outcomes and reduced long‐term costs of diabetes‐related complications.

Diabetes Obesity and Metabolism
University of East Anglia (GB), University of Leeds (GB), University of Nottingham (GB), Imperial College Healthcare NHS Trust (GB), University of Leicester (GB), University of Cambridge (GB), Leeds Teaching Hospitals NHS Trust (GB), Norfolk and Norwich University Hospital (GB), Norfolk and Norwich University Hospitals NHS Foundation Trust (GB), University Hospitals of Leicester NHS Trust (GB), Cambridge University Hospitals NHS Foundation Trust (GB), University of Manchester (GB), University of Oxford (GB), Manchester University NHS Foundation Trust (GB), East Suffolk and North Essex NHS Foundation Trust (GB), Sheffield Teaching Hospitals NHS Foundation Trust (GB), University Hospitals of Derby and Burton NHS Foundation Trust (GB), Ipswich Hospital (GB), NIHR Leicester Biomedical Research Centre (GB), Imperial College London (GB), Hull York Medical School (GB), University of Sheffield (GB)
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon